<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One hundred and four patients with malignant <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> and 5,690 control subjects were screened for the presence of <z:hpo ids='HP_0012115'>Hepatitis</z:hpo> B surface antigen (HBsAg) in their sera </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0005523'>Lymphoproliferative disorders</z:hpo> included in the study were <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (ALL), non Hodgkin's <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> (NHL), <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (CLL), <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>), Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM) </plain></SENT>
<SENT sid="2" pm="."><plain>Screening was done by the Reverse Passive Haemagglutination method using the Welcome kit </plain></SENT>
<SENT sid="3" pm="."><plain>The percentage antigenaemia in the patients and control subjects were 35.6 and 7.7% respectively (p less than 0.0001) </plain></SENT>
<SENT sid="4" pm="."><plain>Using the Odds ratio the relative risk was found to be 6.75 </plain></SENT>
<SENT sid="5" pm="."><plain>The Odds ratio for individual disorders ranged from 2.8 to 9.17 </plain></SENT>
<SENT sid="6" pm="."><plain>The results suggest an association between <z:hpo ids='HP_0012115'>Hepatitis</z:hpo> B surface antigenaemia and malignant <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> and highlights the risk involved in handling specimens from the patients </plain></SENT>
</text></document>